Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/19/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator
(NYSE: BHVN) Delayed: 13.62 -0.27 (1.94%)
Previous Close $13.89    52 Week High $ 
Open $14.07    52 Week Low $ 
Day High $14.37    P/E N/A 
Day Low $13.46    EPS $ 
Volume 6,431,852